NCT05252572
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies
Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies
Zhejiang University·Early Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- AML
- Drug/Device/Intervention
- CLL1 CAR T-cells
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- Zhejiang University
- Location
- Hangzhou,Hangzhou, China
Timeline & enrollment
- Phase
- Early Phase 1
- Start date
- Feb 28, 2022
- End date
- Nov 30, 2024
- Enrollment
- 36 participants
Primary outcome
Dose-limiting toxicity (DLT),Incidence of treatment-emergent adverse events (TEAEs)
Summary
Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of
 CLL1-positive Hematological Malignancies
ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05252572
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05252572 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Zhejiang University and is currently Recruiting. The study focuses on AML. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.